insights_auto
Why is MVIR up 2,33%?
Dive Deeperchevron_right
MVIR:STO
Medivir AB
1,49 SEK
arrow_upward
+2,33%(+0,034) 1D
9-окт., 17:29:42 GMT+2 · SEK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for MVIR...
Open
1,47 SEK
High
1,50 SEK
Low
1,45 SEK
Mkt. cap
932,52 млн
Avg. vol.
1,41 млн
Volume
1,73 млн
52-wk high
2,88 SEK
52-wk low
0,34 SEK
EPS
-0,37 SEK
Shares outstanding
624,18 млн
No. of employees
6
Open
1,47 SEK
High
1,50 SEK
Low
1,45 SEK
Mkt. cap
932,52 млн
Avg. vol.
1,41 млн
Volume
1,73 млн
52-wk high
2,88 SEK
52-wk low
0,34 SEK
EPS
-0,37 SEK
Shares outstanding
624,18 млн
No. of employees
6
News stories
From web sources and news partners
TradingView
·
1 саат мурун
Key facts: NASDAQ:SPCX to buy 800MHz spectrum; developing non‑GEO D2D
Yahoo Finance
·
10 саат мурун
A COVID Vaccine Stock on the S&P 500 Is Up 600% This Year
24/7 Wall St.
·
23 саат мурун
Why "VOO and Chill" Lost Money for 8 Straight Years: What $100,000 in the S&P 500 Did From 2000 to 2008
MarketWatch
·
21 саат мурун
S&P 500 at 10,000 or bust: New ETF offers investors all-or-nothing bet on the index
Profile
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
About Medivir AB